Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?

Present and future of FDG-PET/CT in ovarian cancer

“…Risum et al [42] demonstrated that when FDG-PET/CT is used for preoperative evaluation of patients with advanced ovarian cancer (stage III and IV), the number of patients diagnosed with stage IV increases and stage migration is likely to occur and that the median overall survivals of PET/CT stage III and stage IV were 30.5 and 29.9 months, respectively. They also reported that using univariate analysis, PET/CT stage IV (p = 0.03), complete debulking (no macroscopic residual tumor) (p = 0.002), and performance status (p = 0.04) were statistically prognostic variables, whereas using multivariate Cox regression analysis, complete debulking was the only statistically significant independent prognostic variable (p = 0.02).…”

PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison

“…Additionally, many studies have established the role of 18 Ffluorodeoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) for different gynaecological cancers, either for staging and monitoring treatment response [11][12][13]. MRI, due to its higher soft tissue contrast, was proven superior for characterization of adnexal masses and loco-regional tumour staging, e.g.…”

Survival of ovarian cancer patients in Denmark: Results from the Danish gynaecological cancer group (DGCG) database, 1995–2012

“…Finally, the increased proportion of stage IV cancers may be partly due to diagnostic advancements, e.g. PET/CT scanning, which could counterbalance with increased upstaging [21].…”